Log on / register
Feedback | Support | My details
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G, Xu E, Thipphawong J, Gupta SK
BMC Clin Pharmacol 2007, 7:2
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research article    
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain
Hanna M, Tuca A, Thipphawong J
BMC Palliative Care 2009, 8:14 (15 September 2009)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.


Research article    
A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain
Hanna M, Thipphawong J, the 118 study group
BMC Palliative Care 2008, 7:17 (31 October 2008)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]

This article is also cited by a further 1 article in PubMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.